LAVA Therapeutics (LVTX) announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia, AML, and myelodysplastic syndrome, MDS.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX:
- LAVA Therapeutics to Transition to U.S. Domestic Issuer
- Lava Therapeutics price target lowered to $2 from $6 at H.C. Wainwright
- Lava Therapeutics downgraded to Market Perform from Outperform at Leerink
- Lava Therapeutics downgraded to Market Perform from Outperform at JMP
- LAVA Therapeutics Reports Increased Losses Amid Declining Revenues
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue